Latest news with #shareholder
Yahoo
5 hours ago
- Business
- Yahoo
Those who invested in AbbVie (NYSE:ABBV) five years ago are up 126%
It hasn't been the best quarter for AbbVie Inc. (NYSE:ABBV) shareholders, since the share price has fallen 11% in that time. But at least the stock is up over the last five years. However we are not very impressed because the share price is only up 84%, less than the market return of 102%. Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During five years of share price growth, AbbVie actually saw its EPS drop 16% per year. This means it's unlikely the market is judging the company based on earnings growth. Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics. On the other hand, AbbVie's revenue is growing nicely, at a compound rate of 6.2% over the last five years. In that case, the company may be sacrificing current earnings per share to drive growth. You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). AbbVie is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. If you are thinking of buying or selling AbbVie stock, you should check out this free report showing analyst consensus estimates for future profits. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of AbbVie, it has a TSR of 126% for the last 5 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence! AbbVie provided a TSR of 10% over the last twelve months. But that return falls short of the market. If we look back over five years, the returns are even better, coming in at 18% per year for five years. It's quite possible the business continues to execute with prowess, even as the share price gains are slowing. It's always interesting to track share price performance over the longer term. But to understand AbbVie better, we need to consider many other factors. Case in point: We've spotted 5 warning signs for AbbVie you should be aware of. We will like AbbVie better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
8 hours ago
- Business
- Associated Press
Mr. Gad Forced to Once Again Set the Record Straight at Paragon – Hopefully For the Last Time
Encourages All Stockholders to Vote on the BLUE Proxy Card Ahead of the Company's Annual Meeting NEW YORK, NY / ACCESS Newswire / June 27, 2025 / Hesham 'Sham' Gad, who beneficially owns approximately 28.2% of the outstanding shares of common stock of Paragon Technologies, Inc. ('Paragon' or the 'Company') (OTC PINK:PGNT) and is Paragon's largest stockholder, today issued a statement regarding the incumbent directors' latest, desperate attempt to avoid accountability and mislead stockholders ahead of the Company's upcoming 2025 Annual Meeting: 'This morning, less than one business day before the Company's Annual Meeting, I was informed that the incumbent directors wanted to immediately dispense with over $500,000 of the Company's cash to purchase insurance. The urgency and timing of this decision raise serious concerns. Think about this: why would directors - who own little equity and may not be elected at the Annual Meeting on Monday - call an immediate board meeting to cause Paragon to spend this much shareholder money? This latest move appears to follow a troubling pattern. From implementing a poison pill and issuing stock grants, to now spending hundreds of thousands of shareholder dollars on a last-minute policy, the actions of this Board increasingly seem aimed at shielding themselves rather than serving the long-term interests of Paragon and its owners. Our shareholders know better - this is not about them, but simply another effort, to benefit these directors at shareholder expense. It is disappointing, though not surprising, to see the current Board of Paragon once again resort to misinformation and personal attacks to avoid accountability. To be clear, I have never objected to the Company having reasonable D&O insurance policies, and in fact, we have had sufficient coverage for years evidenced by the simple fact that for over a decade Paragon has NEVER had single D&O claim under my leadership. What has changed is not the Company's exposure, but the risks introduced by the behavior of this Board. On the other hand, as a significant stockholder, I care very deeply about protecting the Company from BOTH risk and wasteful spending - two elements this Board has exposed the Company to in spades. The Board in hastily approving this self-serving purchase disregarded the Company's own governing documents, our settlement agreement, and potentially their fiduciary duties. In doing so, they continue to validate why they are so out of touch with Paragon shareholders. As such, it was vital I advised them of their violations and potential liability exposure. This Board has used substantial Company resources first to entrench themselves, then to defend that entrenchment, and now, just days before the Annual Meeting, to attempt to insulate themselves from the consequences of their poor leadership. As we approach the Annual Meeting, this episode highlights exactly why change is needed. We need leadership that focuses on transparency, fiscal responsibility, and long-term value - not self-preservation. We encourage our fellow stockholders to continue voting on the BLUE card for a slate of directors that values transparency, progress and fulfilling its obligation to act in the best interest of stockholders. We thank you for your consideration and support to date. Let's work together to build something stronger - for today and for the future.' PLEASE VOTE YOUR BLUE PROXY CARD TODAY. Further information and resources in connection with Mr. Gad's campaign for change, accountability and a stockholder-first culture at Paragon are available at For inquiries, please reach out to the address below: [email protected] Saratoga Proxy Consulting LLC John Ferguson (212) 257-1311/(888) 368-0379 [email protected] SOURCE: Sham Gad press release
Yahoo
a day ago
- Business
- Yahoo
Dell (DELL) Strengthens Capital Return with Increased Dividend
Dell Technologies Inc. (NYSE:DELL) is one of the 10 cheap Jim Cramer stocks to invest in. On June 17, the company announced a quarterly cash dividend of $0.525 per common share, payable on August 1 to shareholders recorded as of July 22. The company raised its annual cash dividend by 18% to $2.10 per common share after receiving board approval in February. In the last quarter, Dell (NYSE:DELL) returned $2.4 billion to shareholders, including the repurchase of 22.1 million shares at an average price of $90 per share and a dividend payment of approximately $0.53 per share. As of the FQ1 2026, the company has paid out $13.2 billion to its shareholders through buybacks and dividends since the beginning of FY2023. A team of IT experts discussing the latest network security trends over a laptop screen. Discussing the company on June 9, Cramer stated: 'So traders say if I can't make money after Broadcom reporting a great quarter, the playbook says time to move into the lower quality, cheaper stocks that are less likely to disappoint or should never have been down to begin with. I understand the sentiment, but the problem is that these stocks have already rallied pretty hard, too. Take Dell. It reported an excellent quarter on May 29th… Stock initially failed to rally, but that's because it had run up into the quarter… Dell Technologies (NYSE:DELL) develops and sells a broad range of hardware, software, and services, including storage systems, servers, networking equipment, personal computers, peripherals, and customer support solutions. The company also provides financing options, subscription-based services, and various consumption models. While we acknowledge the potential of DELL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Wall Street Journal
a day ago
- Business
- Wall Street Journal
Mediobanca Aims to Boost Profit, Payouts in Bid to Fend Off Monte Paschi
Mediobanca MB -1.24%decrease; red down pointing triangle said it is targeting higher profits and shareholder payouts over the next three years, as the Italian bank touted its standalone growth prospects in a bid to fend off an unsolicited takeover bid from Monte dei Paschi. The bank–formally known as Mediobanca Banca di Credito Finanziario–said Friday that its plan for the next three years calls for revenue of more than 4.4 billion euros, equivalent to $5.15 billion, net profit of 1.9 billion euros and a return on tangible equity–a key profitability metric for banks–of 20% in the year ending June 2028.
Yahoo
2 days ago
- Business
- Yahoo
Why Nature's Sunshine (NATR) Shares Are Getting Obliterated Today
Shares of wellness products company Nature's Sunshine (NASDAQ:NATR) fell 8.5% in the afternoon session after the company announced the pricing of a secondary stock offering by a major shareholder. The offering involves major shareholder Fosun Pharma USA selling up to 2.85 million shares at a price of $12.00 per share. The stock is trading down to align with the offering price, which represents a significant discount to its previous closing price. While the company itself is not selling any new shares and will not receive any proceeds, the large block of stock hitting the market is creating selling pressure. Nature's Sunshine did note that it may buy back up to $15 million worth of shares from the offering as part of its existing repurchase program, which could help absorb some of the supply. The shares closed the day at $14.30, down 3.1% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Nature's Sunshine? Access our full analysis report here, it's free. Nature's Sunshine's shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 24 days ago when the stock dropped 7.2% on the news that CEO Terrence Moorehead, announced his decision to step down from his role. The board also announced the search for his successor, and Moorehead will remain in his role until a new CEO is appointed. This interim period introduced leadership uncertainty, something the market generally dislikes. Nature's Sunshine is down 4.3% since the beginning of the year, and at $13.94 per share, it is trading 20% below its 52-week high of $17.43 from November 2024. Investors who bought $1,000 worth of Nature's Sunshine's shares 5 years ago would now be looking at an investment worth $1,758. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
